Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics (NASDAQ: RNAC) announced inducement option awards to five new employees.

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) announced inducement option awards to five new employees. On May 1, 2026 the company issued options to purchase an aggregate of 317,200 common shares at an exercise price of $6.22, the closing price that day.

The options were approved by the board, granted under the Amended and Restated 2018 Employment Inducement Incentive Award Plan, vest 25% on May 1, 2027 then in thirty-six substantially equal monthly installments to fully vest on May 1, 2030, and carry a ten-year term. Grants were made under Nasdaq Rule 5635(c)(4).

Argus May 4 session

+11.41% close to close Open Argus

Details

News Market Reaction – RNAC

In the May 4 session, RNAC gained 11.41%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +11.4% in the session following this news. A strong positive reaction aligns with R...

Analysis

The stock surged +11.4% in the session following this news. A strong positive reaction aligns with RNAC’s history of outsized moves around corporate updates, even when the news itself is operational. Prior inducement grant announcements have produced modest and mixed moves, while major financial and clinical updates have driven larger swings. If a sharp gain followed this HR-related grant, investors would need to consider factors like prior volatility, high expectations tied to late-stage trials, and how quickly enthusiasm for incremental news had faded in past episodes.

Key Figures

Inducement options granted: 317,200 options Exercise price: $6.22 per share Employees receiving grants: 5 employees +5 more

Inducement options granted

317,200 options

Aggregate grants to five new employees on May 1, 2026

Exercise price

$6.22 per share

Equal to Nasdaq closing price on May 1, 2026

Employees receiving grants

5 employees

New hires receiving inducement stock options

Initial vesting

25%

Cliff vesting on May 1, 2027

Subsequent vesting period

36 monthly installments

After initial 25% vests, through May 1, 2030

Option term

10 years

Expiry ten years from the May 1, 2026 grant date

Full vesting date

May 1, 2030

Date on which options become fully vested

Plan year

2018

Amended and Restated 2018 Employment Inducement Incentive Award Plan

Historical Context

5 past events · Latest: Apr 30

5 events

1. Apr 30

   Q1 2026 earnings

   24h Move

   -3.9%

   Quarterly results with higher R&D, widened net loss, and updated cash runway.

2. Apr 02

   Inducement grants

   24h Move

   -2.0%

   Inducement stock options totaling 52,450 granted to two new employees.

3. Mar 09

   FY 2025 earnings

   24h Move

   +31.7%

   Full-year 2025 update highlighting cash of $126.9M and late-stage pipeline progress.

4. Feb 23

   Investor conferences

   24h Move

   +0.7%

   Participation in multiple investor conferences and related presentations in early 2026.

5. Feb 03

   Inducement grants

   24h Move

   +2.1%

   Grants of 12,050 inducement options to new employees under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cell therapy

1 terms

cell therapy medical

"a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2026, the Company issued to these employees options to purchase an aggregate of 317,200 shares of the Company’s common stock with an exercise price of $6.22, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on May 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on May 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cartesian Therapeutics (RNAC) announce on May 4, 2026 regarding employee awards?

They announced inducement option grants totaling 317,200 shares to five new employees on May 1, 2026. According to the company, the options carry a $6.22 exercise price equal to the closing market price on the grant date and were board-approved.

How do the inducement options for RNAC vest and when do they fully vest?

Options vest 25% on May 1, 2027, then in thirty-six substantially equal monthly installments to full vesting on May 1, 2030. According to the company, that schedule applies to the 317,200-share inducement awards issued under its 2018 inducement plan.

What is the exercise price and term of the RNAC inducement options granted May 1, 2026?

The exercise price is $6.22 per share and each option has a ten-year term. According to the company, $6.22 equals the closing trading price on the grant date and the awards were made under the inducement award plan.

Do the RNAC inducement option grants cause shareholder dilution?

The grants may cause dilution depending on future option exercises relative to total shares outstanding at exercise. According to the company, 317,200 options were issued, but the announcement does not state an immediate increase in outstanding shares or provide a post-grant share count.

Where can investors find the full details of Cartesian Therapeutics' (RNAC) inducement awards?

Investors can review the company's SEC filings and Nasdaq disclosures for RNAC for full terms and approvals. According to the company, the awards were granted under Rule 5635(c)(4) and the Amended and Restated 2018 Employment Inducement Incentive Award Plan.